The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
The WIN 2026 Symposium will bring together experts to explore advances in precision oncology and strategies for improving personalized cancer care. The symposium, themed Precision Oncology: Innovation and Equity Across the Globe, will feature an international lineup of distinguished oncology and biomedical research leaders.
Four outstanding oncology professionals receive 2026 ESMO awards for their contributions to cancer research, clinical care, and community leadership. The awards recognize pioneering work in cancer prevention, early detection, and immunotherapy.
The Alliance for Clinical Trials in Oncology has released a film highlighting the importance of clinical trials in cancer research, featuring the story of a lung cancer patient who participated in a trial. The film emphasizes the human element of research and explores how individual participation contributes to progress in cancer care.
The BMJH Sankalp Center for Paediatric Haematology Oncology has achieved JACIE certification, a landmark milestone for haematopoietic cell transplantation and cellular therapy in India. This certification ensures safe and effective care for children with life-threatening blood disorders.
The NRG-GU005 trial shows that SBRT improves bowel health related quality of life in localized intermediate risk prostate cancer patients, with no significant impact on urinary HRQOL. SBRT is also associated with lower incontinence related quality of life and improved maintenance of erectile dysfunction compared to hypofractionated IMRT.
The NRG-LU005 trial found that patients receiving twice-daily radiation experienced a more favorable quality-of-life trajectory than those receiving once-daily radiation. This association remained after adjusting for patient characteristics, although the radiation schedule was not randomized.
NRG Oncology receives a perfect grant score of 10 and increased funding from the National Cancer Institute to continue its practice-changing clinical trials. The organization's focus on sex-specific malignancies has led to exceptional progress in cancer research.
NGR Oncology has appointed multiple new leadership members to various subcommittees, including Rebecca Arend as Gynecology Oncologist Vice Chair of the Translational Science Committee and Robin Lockhorst as Chair of the Pharmacy Subcommittee. David Miyamoto was also appointed Radiation Oncology Vice Chair of the Translational Science C...
Exercise oncology identifies anti-tumor mechanisms that can be translated into therapies independent of exercise itself. Mechanistic insights from exercise research inform translational opportunities in areas like metabolic remodeling, gut microbiome manipulation, and immune signaling.
A new study found that a virtual smoking cessation treatment program nearly doubled quit rates for cancer patients who currently smoke. The program, delivered at community oncology care settings, was both cost-effective and satisfying for patients. Participants who completed more sessions had a higher likelihood of quitting.
The study demonstrated significant clinical benefits for patients, with single treatments leading to meaningful reductions in moderate-to-severe symptoms. Patient satisfaction was exceptionally high throughout the program, with over 80% strongly agreeing they were satisfied with the services.
A nationwide analysis found that many radiation oncology clinics have closed, particularly in rural communities, reducing access to lifesaving cancer treatment. The study suggests that understanding which communities are most vulnerable can help policymakers develop strategies to preserve access.
A new study found that over 50 million Americans live in counties without a radiation oncology clinic, highlighting vulnerabilities in the nation's cancer care infrastructure. Radiation oncology practices have closed disproportionately in rural areas and freestanding settings, raising concerns about patients' access to cancer care.
Afzalbek Fayzullaev, a second-year Boston University medical student, has been awarded the ASTRO Medical Student Fellowship Award to conduct an eight-week mentored research project in radiation oncology. He aims to investigate the readability of patient education materials and their impact on treatment adherence.
Gustave Roussy and The Lancet launch a landmark international lecture series in oncology, focusing on personalised prevention. Renowned expert Professor Timothy R. Rebbeck will deliver a lecture on tailored cancer prevention strategies.
A survey of healthcare professionals revealed limited cardio-oncology training during undergraduate and postgraduate education, with only 10% reporting exposure to the subject during medical school. The study highlights the need for standardised educational programmes to address cardiovascular side effects of cancer therapies.
A meta-analysis of studies found that guideline-recommended heart failure therapies protect heart function in patients treated for cancer. RAAS inhibitors and beta-blockers improved left ventricular ejection fraction, while mineralocorticoid antagonists showed encouraging protective effects.
Terasaki Institute researchers and key pioneers publish comprehensive review on glioma organoid models, proposing a foundational classification framework to guide translational brain tumor research. The review provides an overview of human glioma organoid systems and aims to address methodological heterogeneity in the field.
Valsamo Anagnostou, Jordan Berlin, and Olisaemeka Ogbue receive ECOG-ACRIN's Young Investigator Award, Remarkable Mentor in Oncology Award, and Paul Carbone, MD Fellowship Award for outstanding contributions to translational research, mentorship, and improving cancer care. The awards are funded by the ECOG Research & Education Foundation.
Dr. Nageatte Ibrahim brings her expertise in immunotherapy and cancer drug development to HonorHealth Research Institute, focusing on advancing novel treatments and improving patient outcomes. The institute aims to develop collaborations with leading research centers worldwide to bring cutting-edge therapies to patients in need.
A Phase 3 trial showed a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination. The treatment improved median progression-free survival and overall survival, with nearly 75% of patients alive at 18 months.
The NRG Oncology trial showed a sustained overall survival benefit for patients with advanced or recurrent endometrial cancer treated with pembrolizumab and chemotherapy, even after post-study immunotherapy. The benefit persisted in both mismatch repair proficient and deficient populations.
Researchers from Mount Sinai will present various studies on myelofibrosis, lung cancer, multiple myeloma, urothelial cancer, gynecologic cancers, and care innovation. Key findings include selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis and efficacy of HLX43 in advanced non-small cell lung cancer.
Dr. Sharon Giordano and Dr. Eduardo Vilar-Sanchez receive ASCO Special Awards for their transformative work in breast cancer research and prevention, respectively. Their contributions advance understanding of cancer and improve patient outcomes.
Researchers will present over 30 studies on precision oncology, early cancer detection and AI-powered personalized care. Featured topics include biomarker-driven treatments for bladder and lung cancers, new approaches for triple-negative breast cancer and AI-enabled analysis of tumor microenvironment in colon cancer.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
The ASTRO Annual Meeting will take place in Boston from September 26-30, featuring research presentations, keynote addresses, and panel discussions on critical cancer care issues. The meeting aims to foster meaningful conversations about radiation therapy's value in advancing patient care.
The review highlights how retrieval-augmented generation can improve the accuracy, transparency, and clinical reliability of AI tools in cancer care. RAG-enhanced systems produced more accurate results than standard AI models across multiple studies.
Independent academic clinical trials are essential for improving patient outcomes, reducing inequalities in care, and strengthening healthcare systems. The Lancet Oncology Commission aims to deliver actionable recommendations to ensure these trials continue to benefit patients and society worldwide.
Proteomics-driven precision oncology combines multi-omics integration to reveal tumor heterogeneity and functional regulatory networks. Emerging single-cell and spatial proteomics technologies with AI analysis facilitate clinically relevant biomarker discovery.
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
Oncology services are often excluded from emergency health priorities, resulting in delayed diagnosis and treatment interruptions. Vulnerable populations, including women and children, face advanced disease stages due to delays in care.
A team led by Professor Julia Beatty explores how feline tumour viruses offer vital insights into human oncology and viral carcinogenesis. Domestic cat hepatitis B virus is strongly associated with feline HCC, mirroring human HBV oncogenic patterns.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
Nancy L. Lewis, MD, MBS, FACP, a renowned biomedical researcher and clinical trials expert, has been appointed as the new Chief Scientific Officer of the National Comprehensive Cancer Network (NCCN). She will oversee NCCN's programs to advance clinical trials and improve cancer care outcomes globally.
A new article in JMIR Publications showcases precision oncology's success, where individualized multi-drug regimens improve treatment responses and survival rates for patients with advanced cancers. The study found that closely matching drug therapies to tumor mutations leads to better outcomes, while also offering a safer profile.
NRG Oncology has appointed Dr. John Nakayama as Vice Chair of the NRG Ancillary Projects Committee, Dr. Ibrahim Nassour as Vice Chair of the Surgical Oncology Committee, and Dr. Scott Okuno as Vice Chair of the Sarcoma Subcommittee. Dr. Angeles Alvarez Secord was also appointed Chair of the Investigator & Career Development Committee.
Dr. Lisa G. Roth, MD has joined Hassenfeld Children’s Hospital at NYU Langone and Perlmutter Cancer Center as director of the Division of Pediatric Hematology-Oncology. She will oversee clinical care, research, and education programs while expanding access to advanced therapies and clinical trials.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has been awarded a $3 million National Cancer Institute Career Development Award to support early-career oncology researchers focused on improving cancer outcomes for patients from diverse backgrounds. The program, called Advancing Oncology Research C...
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Peter WT Pisters, MD, receives the prestigious Charles M. Balch, MD, Distinguished Service Award for his substantial contributions to surgical oncology through service, research, and leadership. He is recognized as a renowned cancer surgeon, researcher, and hospital administrator.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
The integration of OMOP Oncology into Mayo Clinic Platform enables faster analysis of complex cancer data, unlocking deeper insights and accelerating research. This expansion supports the development of next-generation therapies for patients worldwide.
A Phase II study presents significant overall survival benefits for women with platinum-resistant ovarian cancer treated with elenagen plus gemcitabine. Longer exposure to elenagen correlates with longer survival after treatment discontinuation, suggesting a fundamentally different therapeutic approach.
Halle Zhang joins Insilico Medicine to lead global clinical development strategy for the company's oncology portfolio. She brings over 20 years of experience in oncology clinical development and a track record of advancing therapies through registrational trials.
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.
Researchers identified a targetable driver of brain metastases in inflammatory breast cancer, promoting tumor invasion and triggering brain inflammation via the CXCR2 signaling pathway. Targeting sEcad or the CXCR2 pathway may treat or prevent brain metastasis.
Sujuan Ba, CEO of the National Foundation for Cancer Research, has been recognized as one of OncoDaily's 100 Most Influential CEOs in Oncology in 2025. Under her leadership, NFCR has strengthened its role as a strategic accelerator of cancer research, supporting innovative science and fostering cross-sector collaboration.
NRG Oncology has added several new leadership members to its Brain Tumor, Breast Cancer, Genitourinary Cancer, Lung Cancer, Medical Oncology, and Translational Science committees. Deborah K. Armstrong will lead the NRG Medical Oncology Committee, while Daniel P. Cahill will serve as Surgical Oncology Vice Chair of the NRG Brain Tumor C...
Insilico Medicine collaborates with Servier to develop novel therapeutics in oncology through AI-driven platform Pharma.AI. The partnership is focused on identifying promising targets and generating molecular structures with desired properties.
The American Society for Radiation Oncology (ASTRO) has rebranded its research foundation as Speed of Light – The ASTRO Foundation, marking a renewed focus on advancing research and improving patient care. The new initiative aims to strengthen research collaborations and investments to drive progress in radiation oncology.
A new study by researchers from the Germans Trias i Pujol Research Institute provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer. The review highlights molecular, cellular, and tumour microenvironment factors that explain the therapeutic dichotomy between the two tumour types.
Researchers at UT Health Sciences Center have developed an AI-enhanced platform called ENRICH, which leverages advanced analytics with community-based human support to reduce treatment interruptions and improve cancer outcomes. The program identifies patients at highest risk for interruption and deploys targeted support resources.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
A new study by University of Texas M. D. Anderson Cancer Center researchers has identified a myeloid mimicry pathway that drives tumor hyper progression following immunotherapy in renal medullary carcinoma, highlighting specific targets for overcoming treatment resistance.
Zanidatamab demonstrated significant efficacy in patients with HER2-positive biliary tract cancer, achieving response rates of up to 51.6% and improving symptoms such as pain levels. The trial's results support the emerging role of zanidatamab as a treatment paradigm for this rare and aggressive cancer.